NeuroPace (NPCE) Cash & Equivalents (2020 - 2026)

NeuroPace's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 45.3% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $14.8 million (down 45.3% YoY), while the FY2025 annual figure was $21.7 million, up 61.52% from the prior year.
• Cash & Equivalents was $14.8 million for Q1 2026 at NeuroPace, down from $21.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $27.0 million in Q1 2025 to a low of $5.7 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $13.5 million across 5 years, with a median of $13.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 81.75% in 2022, then surged 173.4% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $6.6 million in 2022, then soared by 173.4% to $18.1 million in 2023, then retreated by 25.63% to $13.4 million in 2024, then soared by 61.52% to $21.7 million in 2025, then slumped by 31.87% to $14.8 million in 2026.
• The last three Cash & Equivalents figures came in at $14.8 million (Q1 2026), $21.7 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.